Therapeutic area intelligence for Acute Lung Injury with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Companies: 2

Companies

PIP-2 →

veterinary pharmaceuticals →

Assets

No related entities indexed yet.

Recent signals(2)

ClinicalAugust 3, 2026

In Vitro Study on PIP-2 for Immune Cell Blockade in ARDS Patients

An in vitro study will assess the effects of PIP-2 on immune cell activation in ARDS patients.

StrategyJuly 24, 2026

Study Reveals Mechanism of Herbal Extracts in Treating Acute Lung Injury in Poultry

The study identifies that Lonicerae Japonicae Flos and Forsythiae Fructus extracts alleviate LPS-induced acute lung injury in broilers by suppressing MAPK signaling and regulating apoptosis.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.